Objective. To evaluate the efficacy of
Goshajinkigan for
oxaliplatin-induced
peripheral neuropathy in
colorectal cancer patients. Patients.
Colorectal cancer patients (N = 29) who received ≥4 weeks of
Goshajinkigan for
oxaliplatin-induced
peripheral neuropathy during
chemotherapy at Kyoto Prefectural University of Medicine were (
Goshajinkigan group) compared to 44 patients who had not received
Goshajinkigan during the same period (non-
Goshajinkigan group). Main Outcome Measures. The effect of
Goshajinkigan was graded as curative, effective, stabilizing, or deleterious. The relationships between the grade of
peripheral neuropathy and the dose of
oxaliplatin in the
Goshajinkigan and non-
Goshajinkigan groups were evaluated. Results. The effect of
Goshajinkigan on
peripheral neuropathy in the
Goshajinkigan group was curative, effective, stabilizing, and deleterious in 3.4, 20.7, 69.0, and 6.9% of patients, compared to the effect in the non-
Goshajinkigan group (4.5, 15.9, 45.5, and 34.1%). The ratio of deleterious effects was significantly different between these two groups (P = 0.04). A Kaplan-Meier analysis in relation to the cumulative dose of
oxaliplatin showed that the incidence of grade 3
peripheral neuropathy tended to be less in the
Goshajinkigan group (P = 0.05). There were no significant differences in
time to treatment failure and severe adverse events between these two groups. Conclusions.
Goshajinkigan prevented exacerbation of
oxaliplatin-induced
peripheral neuropathy. This trial is registered with UMIN000009956.